New York Times Narcolepsy Article Features New Treatment Option

On September 9, 2026, The New York Times published an in‑depth feature on the FDA approval of oveporexton (commercial name Orzeyful), the first‑of‑its‑kind orexin agonist designed to address the underlying cause of type 1 narcolepsy. This moment has been decades in the making, and it represents a major step forward for people living with the profound sleepiness of narcolepsy, among other symptoms.

The article highlights the lived experience of Julie Flygare, President and CEO of Project Sleep, who was diagnosed with narcolepsy in 2007. Julie shared how pervasive sleepiness affects every part of daily life and how emotions such as laughter, surprise, or irritation can trigger cataplexy, causing her muscles to go slack without warning.

For years, Julie and many others have hoped for a treatment that does more than manage symptoms. They have been waiting for a therapy that activates orexin signaling, addressing the underlying deficiency. Last month, that hope became reality.

A First-of-its-Kind Treatment

Orzeyful (oveporexton), developed by Takeda Pharmaceutical Company, is the first drug to successfully mimic orexin. In clinical trials, patients stayed awake more than twice as long as they could on currently available medications. Some participants reported being able to take up new hobbies, socialize more easily, or engage in activities that had previously felt out of reach.

Julie participated in one of the trials. She recalled arriving for her first visit unable to think clearly or walk steadily because she had paused her usual medications. After starting the study drug, she noticed a striking shift. She described the wakefulness as having a different tone, something “sunnier” than what she had experienced with stimulants.

Project Sleep’s Role in a Changing Landscape

The New York Times article also highlights Julie’s leadership in founding Project Sleep, which raises awareness of sleep disorders and amplifies patient voices. She began organizing sleep awareness walks at a time when few companies were investing in narcolepsy research. Today, the approval of oveporexton marks a full circle moment. The field is expanding rapidly, with multiple companies pursuing orexin-based treatments and exploring their potential across a wide range of neurological conditions.

Project Sleep continues to advocate for earlier diagnosis, better treatments, and greater public understanding of narcolepsy. National coverage like this reinforces the importance of centering patient experiences and ensuring that scientific breakthroughs translate into real-world support.

Looking Ahead

Orzeyful will be available once the Drug Enforcement Administration completes its scheduling review, expected by November. While many questions remain about long-term effects and the ability of orexin agonists to help people with type 2 narcolepsy, physicians and researchers are optimistic. 

For Julie and the Project Sleep community, this moment reflects years of advocacy, education, and determination and signals a future with better treatment options.

More Recent News on Narcolepsy